Biologic drugs are filling the pipelines of big pharmaceutical companies and niche biotech companies, and many expect the market for these drugs to soar.
But discovery and development of biologics is complex, time-consuming and expensive because they’re derived from living organisms. A new drug discovery company called Invenra Inc. says it has a platform that could overcome some of the barriers that limit the discovery of new biologic drugs in areas like cancer, Alzheimer’s disease and diabetes.
The company disclosed in a securities filing that it has raised $3 million. Unfortunately, there’s not much else known about this Madison, Wisconsin, startup, and co-founder and President Roland Green did not respond to a request for more information.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
According to its website, Invenra says peptide and protein drugs have the potential to hit many previously “undruggable” drug targets because of their molecular structure and size. Its proprietary technology allows the company’s scientists to “screen billions of novel peptides and proteins for intracellular biological activity in less than a week,” Invenra’s site says.
U.S. Securities and Exchange Commission filings reveal that the company, which was formed in 2011, raised $1.2 million last year.
